Pharmacyclics (PCYC)
News
| May 31 | $PCYC http://stks.co/43iw Consolidating very well.. keep an eye on it.. by vjtweet |
| May 31 | Will These 3 Health-Care Doubles Keep Running? Fool |
| May 31 | Tomorrow's Winners Aren't Where You Think |
| May 31 | Europe goes from messy to messier |
| May 30 | Tomorrow's Winners Aren't Where You Think Fool |
| May 29 | $PCYC http://stks.co/41VD Clear buy above 33. Keep an alert there.. by vjtweet |
| May 29 | vicious moves. stopped out of $pcyc -.45. Poor adjustments on my end. by AaronJ |
| May 29 | Worksheet for @stocktwits50 http://stks.co/40or $ARBA $LQDT $HAIN $EXPE $ALLT $ALGT $Z $ACHC $SXCI $PCYC by tradewithpete |
| May 29 | Cash remains king |
| May 28 | Headstart on whats working RT @StockTwits Best StockTwits50 Performers for the week: $ARBA $DDD $PCYC $EXPE $UA $Z http://stks.co/40RM by howardlindzon |
Profile
Exchange: NASDAQCM Sector: Healthcare Industry: Drug Manufacturers - Other
Pharmacyclics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Its clinical development and product candidates are small-molecule enzyme inhibitors designed to target key biochemical pathways involved in human diseases with critical unmet needs. The company has three proprietary drug candidates under clinical development and several preclinical lead molecules which includes Bruton's tyrosine kinase inhibitor, Btk inhibitor lead optimization program and histone deacetylase inhibitor. The company was founded on April 19, 1991 and is headquartered in Sunnyvale, California.
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Pharmacyclics is up 344.8% over the last year vs S&P 500 Total Return up 0.88%, Isis Pharmaceuticals up 7.15%, and Allos Therapeutics down 19.77%.
- PCYC Total Returns
- ^SPXTR Total Returns
- ISIS Total Returns
- ALTH Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these PCYC related companies
Pro Strategies Featuring PCYC
Did Pharmacyclics make it into our Pro Portfolio Strategies?
PCYC Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other PCYC Resources
- Company Website
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| PCYC | 31.42 | -0.68 | -2.12% | 2.209B |
| PCY | 27.70 | +0.03 | +0.09% | |
| PCX | 2.37 | -0.01 | -0.42% | 221.15M |
| PCTI | 6.11 | +0.09 | +1.50% | 111.31M |
| PCS | 6.40 | +0.07 | +1.11% | 2.295B |
| PCRX | 10.62 | -0.05 | -0.47% | 271.12M |
| PCP | 166.21 | -0.41 | -0.25% | 24.19B |
| PCOM | 11.27 | +0.05 | +0.45% | 169.09M |
| PCN | 16.19 | +0.09 | +0.56% | |
| PCM | 10.94 | -0.03 | -0.27% |
